70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016
Published Jun 30, 2016
42 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016, provides in depth analysis on 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
- The report reviews 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
- I

  
Source:
Document ID
GMDHC0264TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Overview61
Therapeutics Development73
  70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Products under Development by Stage of Development71
  70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Products under Development by Therapy Area81
  70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Products under Development by Indication91
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Products under Development by Companies122
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Therapeutics Assessment144
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration161
  Assessment by Molecule Type171
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Companies Involved in Therapeutics Development187
  ArQule, Inc.181
  Astex Pharmaceuticals, Inc.191
  Eddingpharm201
  Merck KGaA211
  PharmAust Limited221
  Phoenix Biotechnology, Inc.231
  Sentinel Oncology Limited241
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Drug Profiles259
  AT-13148 Drug Profile252
  EDP-317 Drug Profile271
  M-2698 Drug Profile281
  monepantel Drug Profile291
  PBI-05204 Drug Profile302
  Small Molecule To Inhibit S6K1 For Breast Cancer Drug Profile321
  Small Molecules to Inhibit S6K for Cancer Drug Profile331
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Dormant Projects341
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Discontinued Products351
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Featured News &Press Releases365
  Jan 29, 2016: PharmAust Limited Announced Quarterly Report &Company Update For the period ended 31 December 2015361
  Nov 26, 2015: PharmAust Appoints GenScript to Complete Further Pre-Clinical Validation for Phase II Trial371
  Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types371
  Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types381
  Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says391
  Jan 22, 2010: ACT BIOTECH Announces FDA Acceptance Of IND For ACTB1003, A First-in-Class Anti-Cancer Therapeutic401
  Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference401
Appendix412
  Methodology411
  Coverage411
  Secondary Research411
  Primary Research411
  Expert Panel Validation411
  Contact Us411
  Disclaimer421

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/70-kDa-Ribosomal-Protein-S6-Kinase-p70S6K-or-EC-2-7-11-1-Pipeline-Review-H1-2016-2088-16131>
  
APA:
Global Markets Direct - Market Research. (2016). 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/70-kDa-Ribosomal-Protein-S6-Kinase-p70S6K-or-EC-2-7-11-1-Pipeline-Review-H1-2016-2088-16131>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.